Japanese pharmaceutical firm Takeda mentioned the European Union had given the inexperienced mild to its dengue fever vaccine, making it the second jab stopping the illness to be permitted by the bloc.
Mosquito-borne dengue could cause hemorrhagic fever and infects an estimated 100 to 400 million individuals yearly, though over 80 % of circumstances are delicate or asymptomatic, the WHO says.
Takeda Pharmaceutical mentioned its vaccine, marketed as Qdenga, was given regulatory approval by the European Fee on Thursday for individuals aged 4 and above, no matter their virus publicity historical past.
One other dengue vaccine, Dengvaxia—the world’s first in opposition to the illness—is already accessible within the European Union, however solely for individuals who have had a beforehand confirmed an infection.
Dengvaxia grew to become the topic of controversy in 2019 when the Philippines banned it over security issues, claims which its maker, French pharmaceutical large Sanofi, denies.
Qdenga was permitted in Indonesia earlier this 12 months for these aged six and up.
The variety of reported dengue circumstances has elevated greater than eightfold within the final 20 years, in line with the World Well being Organisation, which says “about half of the world’s inhabitants (is) now in danger”.
© 2022 AFP
Quotation:
Japanese dengue vaccine turns into second permitted by EU (2022, December 9)
retrieved 9 December 2022
from https://medicalxpress.com/information/2022-12-japanese-dengue-vaccine-eu.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.